207165

Enhanced FasL Pack, Soluble, Recombinant, Human, aa103-281 (Apoptosis Antigen Ligand, APT1LG1, APTL, CD95 Ligand, CD95L, CD95-L, FAS Antigen Ligand, Fas Ligand, CD178, FASLG, Tumor Necrosis Factor Ligand Superfamily Member 6, TNFSF6)

Größe

£735.00

SKU:: 207165
Reinheit:: ~95% (SDS-PAGE)
Lagerbedingungen:: -20°C
Hersteller:: United States Biological
Format:: Supplied as a lyophilized powder from PBS. Reconstitute with sterile dH2O or PBS.
Weitere Details:: FasL, soluble induces apoptosis in a concentration range of <1ng/ml in the presence of 0.1-1ug/ml of TNF Ligands Enhancer. Binds to human and mouse Fas (CD95; APO-1). Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml. Intended Use: Binds to human and mouse Fas (CD95; APO-1). Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml. Specificity: Human and mouse Source: Recombinant protein corresponding to aa103-281 from human FasL, fused to a FLAG®-tag at N-terminal, expressed in HEK 293 cells. Kit Components: FasL, Soluble, Recombinant, Human: 1x10ug TNF Ligands Enhancer: 4x50ug Concentration: FasL: 0.1mg/ml after reconstitution TNF Ligands Enhancer: 1mg/ml after reconstitution Endotoxin Content: FasL: <0.05EU/ug (LAL test; Lonza). TNF Ligands Enhancer: <0.01EU/ug (LAL test; Lonza). Storage and Stability: Lyophilized and reconstituted products are stable for 6 months after receipt at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.